Logo Image
Feature|Videos|December 18, 2025 (Updated: January 14, 2026)

How Codexis is Redefining Pharma Biocatalysis

Mandy Vink, VP of Business Development at Codexis, explains how the company leverages over 20 years of expertise in small molecule APIs to advance biocatalysis across pharma.

Key Objectives

  • Understand how Codexis leverages over two decades of experience with small-molecule APIs to support large pharma partners
  • Learn more about the current trends in small molecule APIs
  • Learn more about the current trends in adopting biocatalysis

Codexis leverages directed evolution and computational biology to develop powerful, sustainable biocatalysts for manufacturing small molecule APIs, a technology critical to partners worldwide and used in drugs like Paxlovid. Mandy Vink, VP of Business Development at Codexis, explores market trends, Codexis’ position in the industry and its collaborations, and what currently drives adoption among innovators and CDMOs.

Related to this article

View more
Regulatory Roundup—September 2026
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Read more